Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as antiĀ–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

ERIS's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 0.885000
forwardPE 29.242357
debtToEquity 75.737000
earningsGrowth 0.322000
revenueGrowth 0.284000
grossMargins 0.752020
operatingMargins 0.249270
trailingEps 25.760000
forwardEps 41.650000

ERIS's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
ERIS's positive growth in earnings and revenue suggests the company is on track to expand its business. These indicators highlight a healthy financial performance, with ERIS expected to increase its market presence and profitability.
ERIS's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
ERIS's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that ERIS is likely to outperform its previous year's financial performance.

Price projections:

Price projections for ERIS
Price projections for ERIS

Price projections for ERIS have steadily increased, reflecting growing optimism about the company's future. This trend suggests that analysts believe ERIS is well-positioned for continued success.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


Analysts are favoring ERIS with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider ERIS as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.